ELOCTATE® is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia A (congenital factor VIII deficiency) for:
- Control and prevention of bleeding episodes.
- Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
- Perioperative management (surgical prophylaxis).
ELOCTATE does not contain von Willebrand factor, and therefore is not indicated in patients with von Willebrand's disease.
ELOCTATE is manufactured using a human cell line, using an environment free of animal and human additives.
ELOCTATE is approved for use for the treatment of Haemophilia A in Australia and New Zealand. It is also approved in the United States, Japan, Canada, and other countries.